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The Journal of Immunology
Network Analysis Identifies Proinflammatory Plasma Cell
Polarization for Secretion of ISG15 in Human Autoimmunity
Matthew A. Care,*,†,1 Sophie J. Stephenson,*,1 Nicholas A. Barnes,*,2 Im Fan,‡
Alexandre Zougman,x Yasser M. El-Sherbiny,{,‖ Edward M. Vital,{,‖ David R. Westhead,†
Reuben M. Tooze,*,‡,3 and Gina M. Doody*,3
Plasma cells (PCs) as effectors of humoral immunity produce Igs to match pathogenic insult. Emerging data suggest more diverse
roles exist for PCs as regulators of immune and inflammatory responses via secretion of factors other than Igs. The extent to which
such responses are preprogrammed in B-lineage cells or can be induced in PCs by the microenvironment is unknown. In this study,
we dissect the impact of IFNs on the regulatory networks of human PCs. We show that core PC programs are unaffected, whereas
PCs respond to IFNs with distinctive transcriptional responses. The IFN-stimulated gene 15 (ISG15) system emerges as a major
transcriptional output induced in a sustained fashion by IFN-a in PCs and linked both to intracellular conjugation and ISG15
secretion. This leads to the identification of ISG15-secreting plasmablasts/PCs in patients with active systemic lupus erythema-
tosus. Thus, ISG15-secreting PCs represent a distinct proinflammatory PC subset providing an Ig-independent mechanism of PC
action in human autoimmunity. The Journal of Immunology, 2016, 197: 000–000.
T
he polarization of immune cell populations for the se-
cretion of distinct profiles of extracellular signaling
molecules to drive and modulate immune responses has
emerged as a recurrent feature across adaptive and innate immunity.
For the B cell lineage, initial descriptions centered on an immune
regulatory function and the secretion of IL-10 (1, 2); more recently,
additional secretory capacity has been identified in murine mod-
els, including the secretion of TNF-a, NO, IL-17, and IL-35 (3–5).
An important feature that distinguishes the B cell lineage
from other cellular populations is the capacity for fundamental
reprogramming toward dedicated high-level secretory capacity
associated with the plasma cell (PC) state. This high-level secretory
activity is first acquired in proliferating PC precursors, known as
plasmablasts, and because exit from cell cycle is the principal
feature separating these cell states, both plasmablast and PC
populations are referred to as Ab-secreting cells (ASCs). The
canonical secretory product of ASCs is their specific Ig; however,
the importance of alternate bioactive secretory products is in-
creasingly being appreciated (6). Such non-Ig secretory activity in
ASCs has been primarily characterized in murine model systems
highlighting specific relationships between selected pathogens and
ASC-derived cytokine secretion. Although in some instances non-
Ig secretory functions have been shown to develop during differ-
entiation to the PC state (3–5, 7), in other instances, the rapidity
with which cytokine-secreting PCs emerged after infectious
challenge suggested the possibility that the response may have
developed in previously established ASCs (8). An ability of ASCs
to respond to environmental cues by acquiring polarized immune
modulatory functions would resemble responses in macrophage/
monocytes, in which functional polarization is determined by the
prevailing milieu and can represent a labile phenotype within a
cell population (9).
In humans, the importance of non-Ig secretory activity from
ASCs is less well characterized. PCs are, however, maintained in a
variety of distinct microenvironmental states including both pri-
mary and secondary lymphoid tissue and tissues undergoing acute
and chronic inflammation. The latter environments are frequently
accompanied by polarization of other lymphoid and innate immune
cell populations for specific secretory activity.
One of the most important autoimmune conditions in which
ASCs play a role is systemic lupus erythematosus (SLE). SLE
shows a strong pathogenic association with both autoantibodies and
IFN responses (10). Evidence for IFNs as immediate drivers of
such pathology is provided by the monogenic IFNopathies, in
which sequence variants in diverse upstream regulators lead to
exaggerated IFN responses and convergence on autoimmune
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features closely related to SLE (7). Type 1 IFN in particular se-
creted by plasmacytoid dendritic cells has been identified as a
factor that can enhance the generation of PCs in vivo (11), and we
and others (12–14) have shown that IFN-a can contribute to the
generation and maintenance of long-lived human PCs in vitro.
Although autoantibodies play an important role in SLE and other
autoimmune pathology, there is considerable interest in defining
potential mechanisms linking the B cell lineage, including ASCs,
to autoimmune pathology that are independent of Igs (15).
An important question also relates to the interaction between type
1 and type 2 IFN-mediated immune responses. Again, monogenic
diseases have been informative in this regard, and the type 1 IFN-
responsive gene IFN-stimulated gene 15 (ISG15) has emerged as
a potentially critical bridge. ISG15 has a complex biology linked,
on the one hand, to covalent intracellular modification of target
proteins, ISGylation, a process analogous to ubiquitinylation, and
on the other hand to a role as an extracellular signaling molecule/
cytokine (16). In the latter role, ISG15 has been known for several
years as an activator of NK cells and a driver of IFN-g secretion
(17, 18). In the context of monogenic disease affecting ISG15 in the
patients so far described, the primary determinant of disease phe-
notype was the presence or absence of Mycobacterium bacillus
Calmette-Gue´rin (BCG) vaccination (19). In the presence of BCG
vaccinations, patients presented with disseminated mycobacterial
infection attributable to the failure of ISG15-dependent extracellular
signaling and IFN-g–driven immune responses. In contrast, the
absence of BCG vaccination in a second set of patients revealed a
critical function for intracellular ISG15 in the inhibition of type 1
IFN responses and mutations in ISG15 led to an IFNopathy (20).
Given the importance of ASCs in SLE, and our identification of
IFN-a as a factor capable of sustaining long-lived PC survival, we
were motivated to dissect the effect of IFN-a in more detail. In this
study, using detailed gene network analysis of the plasmablast to PC
transition, we show that IFN-a provides a potent environmental
signal driving a distinct program of gene expression in PCs, mir-
roring patterns observed in SLE, without globally impacting on the
fundamental processes of entry into cell cycle, quiescence, or the
completion of secretory reprogramming. We identify the sustained
and functional induction of ISG15 and components of ISGylation
machinery (16) as a primary effect of IFN-a on human ASCs.
Critically, this is accompanied by direct secretion of ISG15, a
feature that is also observed in primary human ASCs cultured in the
presence of IFN-a and spontaneously from plasmablasts of patients
with SLE. These data characterize a new population of human in-
flammatory PCs polarized for the secretion of the proinflammatory
mediator ISG15, identifying an Ig-independent mechanism of PC
action in human autoimmunity. This establishes the basic principal
that human PCs are subject to polarization by the microenviron-
mental milieu to acquire the capacity for immune modulation.
Materials and Methods
Abs and reagents
Reagents were human IL-2 (Roche); IFN-g (Sigma-Aldrich); IL-6, IFN-a,
and IL-21 (PeproTech); goat anti-human F(ab9)2 fragments (anti-IgM and
-IgG; Jackson ImmunoResearch Laboratories); HybridoMax hybridoma
growth supplement (Gentaur); Lipid Mixture 1, chemically defined (2003)
and MEM Amino Acids Solution (503; Sigma-Aldrich); CountBright beads
(Invitrogen); and 7-aminoactinomycin D (BD Biosciences). The Abs used for
flow cytometry were Viogreen-conjugated anti-CD3 (BW264/56; Miltenyi
Biotec), PE-conjugated anti-CD19 (LT19; Miltenyi Biotec), V450-conjugated
anti-CD20 (2H7; eBioscience), A700/FITC-conjugated anti-CD27 (M-T271;
BD Biosciences), PE-Cy7–conjugated anti-CD38 (HB7; BD Biosciences),
and allophycocyanin-conjugated anti-CD138 (B-B4; Miltenyi Biotec). Abs used
for biochemical/proteomic evaluation were anti-ISG15 (Proteintech and [3E5]
Santa Cruz Biotechnology), anti-SYK (D1I5Q; Cell Signaling Technology),
histone H3 (Abcam), peroxidase-conjugated goat anti-rabbit IgG (H+L)
(Jackson ImmunoResearch Laboratories), and anti–b-actin (AC15; Sigma-
Aldrich). Immunohistochemical staining was performed using mouse
monoclonal anti-ISG15 (F9; Santa Cruz Biotechnology). The ELISPOT
assay employed a mouse anti-ISG15 (3E5; Santa Cruz Biotechnology)
capture Ab followed by a primary rabbit anti-ISG15 (ProteinTech) and
secondary peroxidase-conjugated goat anti-rabbit detection Abs (Jackson
ImmunoResearch Laboratories) and TMB substrate (Mabtech).
Cell isolation and culture
Peripheral blood was obtained from healthy donors or patients with a
confirmed diagnosis of SLE after informed consent. Approval for this study
was provided by the U.K. National Research Ethics Service via the Leeds
East Research Ethics Committee (approval reference: 07/Q1206/47 as well
as 10/H1306/88 for collection of samples and data from patients with SLE).
Mononuclear cells were isolated by Lymphoprep (Alere) density gradient
centrifugation. Total B cells were isolated from healthy donor samples by
negative selection with the memory B cell isolation kit (Miltenyi Biotec).
Plasmablasts were identified by surface staining for CD19+CD38+CD27+
and sorted using a BD Biosciences Influx. Culture conditions for the
generation of plasmablasts and PCs from peripheral blood human B cells
have been described in detail elsewhere (12). At day 6, cells were treated
with or without IFNs as indicated.
Day 6 plasmablasts were reseeded at 1 3 106 in transwells in media sup-
plemented with IL-6 (10 ng/ml), IL-21 (50 ng/ml), HybridoMax hybridoma
growth supplement (11 ml/ml), Lipid Mixture 1, chemically defined (5 ml/ml),
and MEM amino acid solution (20 ml/ml) on g-irradiated M2-10B4 cells (43
104/well) with either IFN-a (200 IU/ml) or IFN-g (200 IU/ml).
Flow cytometry
Cells were stained with directly conjugated Abs and analyzed on an LSR II
flow cytometer (BD Biosciences). Live cells were gated using forward light
scatter/side scatter characteristics and exclusion of 7-aminoactinomycin D (BD
Biosciences). Controls included isotype-matched conjugated Abs. Absolute
cell counts were performed with CountBright beads (Invitrogen). Data analysis
was performed using FACSDiva Software 8.0 (BD Biosciences).
Gene expression data acquisition and analysis
Total RNA was extracted using TRIzol (Invitrogen), subjected to DNAseI
treatment (DNA Free; Ambion), and subsequently amplified using the
Illumina TotalPrepTM-96 RNA Amplification Kit (Life Technologies).
Labeled cRNAs were hybridized onto HumanHT-12 v4 Expression
BeadChips (Illumina) according to the manufacturer’s instructions and
scanned with the Illumina BeadScanner. Illumina GenomeStudio Gene
Expression Module was employed for initial data processing, and probes
were annotated with approved symbols (HUGO; version 2015/01/14) and
further processed with Lumi (21, 22). Probes not detected on three or more
arrays were removed and the remaining data quantile normalized (n =
21,209 probes). A linear model was fitted to the gene expression data
using the R Limma package (23). Differentially expressed genes between
the contrasts were gauged using the Limma empirical Bayes statistics
module, adjusting for multiple testing using Benjamini and Hochberg
correction.
Network construction and module analysis
The top 2000 most variant probes were used to construct a coexpression
network using the weighted gene coexpression network analysis (WGCNA)
approach (24). An adjacency matrix was constructed using absolute
Pearson correlation coefficient ^ 8 (soft threshold) and converted to a to-
pological overlap matrix (TOM). Modules were identified using cutree-
Dynamic with deepSplit = True, minClusterSize = 8, cutHeight = 0.995,
and method = Tree. Similar modules were merged using mergeClose-
Modules with a cutHeight = 0.2. Generated modules between conditions
were compared using a Fisher exact test to give a heat map showing the
number of overlapping genes between two treatment types, with the
overlaps shown as numbers and the significances as the color scale (2log10
p values). These overlap heat maps were used to recolor the WGCNA
modules so that maximally overlapping modules had the same color.
Network visualization
Node and edge lists output by WGCNA were converted (retaining 50,000
most significant edges) and imported into the Gephi package (25). Nodes
were colored according to the WGCNA module colors, node size scaled
according to Betweenness-centrality, edges colored by WGCNA TOM
weight, and graph layout was carried out using Gephi’s ForceAtlas 2
(LinLog mode, Prevent-Overlap, Edge-Weight-Influence = 1, Scaling =
0.05, Gravity = 1, Tolerance = 5000, Approximation = 1.2).
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Signature enrichment analysis
A data set of 14,154 gene signatures was created by merging signatures
downloaded from http://lymphochip.nih.gov/signaturedb/ (SignatureDB),
http://www.broadinstitute.org/gsea/msigdb/index.jsp MSigDB V5
(MSigDB C1–C7 and H; excluding C5. With MIPS signatures from ver-
sion 3.1 and PID signatures from version 4 added back), http://compbio.
dfci.harvard.edu/genesigdb/ Gene Signature Database V4 (GeneSigDB),
UniProt keywords (downloaded using biomart), and seven papers (26–35).
A gene ontology gene set was created using an in-house python script.
This parses a gene association file (http://geneontology.org/page/download-
annotations) to link genes with ontology terms and then uses the ontology
structure (.obo file; http://purl.obolibrary.org/obo/go.obo) to propagate
these terms up to the root. The resultant gene set contained 19,599 terms.
The gene-ontology and gene-signatures sets were merged to give a final
signature set of 33,753 terms. Enrichment of gene lists for signatures was
assessed using a hypergeometric test, in which the draw is the gene list
genes, the successes are the signature genes, and the population is the genes
present on the platform.
Module signature enrichment comparison
The expression of the 2000 probes used for network construction was
analyzed across the treatment time courses, summing the log2 expression
values between each consecutive time point and allowing the overall trend
(up/downregulated) of each gene to be assessed. The WGCNA module/
connectivity files were processed to output gene lists, retaining probes with
an SD (across time course) .0.2. Probes in each module were split into
those that had an up/down expression trend, giving two module gene lists
per WGCNA module; lists with less than five genes were discarded.
The genes present in each module gene list were used for signature
enrichment analysis. A representative selection of the most enriched sig-
natures was compared across the modules and treatment types. The en-
richment z-scores were retrieved for all modules per representative
signature, z-scores were set to 0 when the p value .0.05, and any module
with no enriched signature was removed. The matrix was then hierarchi-
cally clustered (Pearson, Complete) using GENE-E (https://www.
broadinstitute.org/cancer/software/GENE-E/).
Connectivity versus expression
Intramodular connectivity and gene expression were compared between
pairs of treatments. The WGCNA modular connectivity was scaled (0–1)
within each module. The Limma T-Statistics was used as a measure of
differential gene expression between treatments at each time point.
Western blotting and proteomic analysis
At the indicated time point, primary cells were harvested, washed with PBS,
and lysed in reducing Laemmli buffer to generate whole-cell lysates.
Alternatively, plasmablasts that had been cultured in the presence of IFN-a
for 24 h were lysed in either RIPA or Nonidet P-40 buffer containing pro-
tease inhibitors. Immmunoprecipitates were prepared from these lysates
using Abs against ISG15, SYK, or isotype controls. Samples were separated
SDS-PAGE and then transferred to nitrocellulose. Abs used to detect ISG15,
SYK, and b-actin were subsequently incubated with the immunoblot and
detected by ECL (SuperSignal West Pico Chemiluminescent Substrate;
Thermo Scientific). ISG15 immunoprecipitates prepared from IFN-a–
stimulated plasmablasts were subject to trypsin digestion by the Strap
method, consequent liquid chromatography tandem mass spectrometry,
and data processing performed as previously described (36).
ELISPOT
For detection of ISG15 secretion, polyvinylidene difluoride plates were
activated with 70% ethanol, washed with sterile water, and then coated with
mouse anti-human ISG15 (1.5 mg/well in sterile PBS) capture Ab overnight
at 4˚C. The plates were then washed with sterile PBS and blocked with
IMDM containing 10% FBS. Plasmablasts were added at the indicated cell
number in media containing IMDM, 10% FBS, IL-21 (50 ng/ml), and IL-6
(10 ng/ml) in the presence or absence of IFN-a (100 U/ml). Plates were
then incubated for 20–24 h in a humidified incubator. Cells were removed
from the plate and followed by a PBS wash. To detect ISG15 secretion,
rabbit anti-human ISG15 was added to each well (0.1 mg/well in PBS
containing 0.5% BSA) and the plates were incubated for 2 h at room
temperature. Alternatively, mouse IgG was used to coat the plates as a
control for nonspecific spot formation. The plate was then washed and
peroxidase-conjugated goat anti-rabbit Ab added (diluted 1:4000 in PBS
containing 0.5% BSA) for 1 h at room temperature. The plate was then
washed, and spots were detected by addition of TMB substrate. Images
were captured using an AID EliSpot Reader System with software version
5.0 (Autoimmun Diagnostika). For detection of human IgG secretion, the
Human ELISpot IgG Plus kit (Mabtech) was used. The assay was per-
formed as described in the manufacturer’s protocol.
Data access
The complete set of array data has been submitted to the National Center for
Biotechnology Information Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo) under accession number GSE75007.
Results
Impact of inflammatory cytokines on PC generation
IFNs are central to both effective immune responses and pathogenic
autoimmunity and represent likely candidates as mediators of the
functional polarization of PC populations. Type 1 IFN has been shown
to support PC differentiation (11, 13), and we previously determined
that inclusion of IFN-a at the plasmablast stage contributed to the
emergence of long-lived human PCs in vitro (12). Developing
plasmablasts also have the potential to be exposed to IFN-g, for
example, in the context of production by T follicular helper cells in
the germinal center (37). Furthermore, it remained unknown whether
IFN exposure impacted on the core processes of PC differentiation
or acted to impose an additional distinct functional signature on a
conserved differentiation pathway. In SLE, it is well established that
the peripheral blood can show signatures indicative of an active IFN
response (30, 38–41), and such responses may in part derive from
circulating ASC populations at the plasmablast to PC transition. We
therefore focused on a detailed analysis of the effects of IFNs at this
final differentiation step of the B cell lineage.
To address this question, we employed our differentiation model
focusing on ASCs undergoing the transition from an actively cycling
population (plasmablasts) to cell cycle quiescence (PCs), as previ-
ously defined in our system (12), and undertook a detailed time-
course analysis of gene expression during this transition. Phenotypic
maturation was monitored by the loss of B cell marker CD20 and
concomitant acquisition of PC markers CD38 and CD138. Within
48 h of initiating the plasmablast to PC transition in media, con-
taining IL-6 and IL-21 alone or supplemented with either IFN-a or
IFN-g, a CD38hiCD138+ population was readily detectable in all
culture conditions (Fig. 1A). The proportion of cells with PC phe-
notype increased with time, reaching ∼90% by day 20. Overall,
there were no consistent differences observed in the cell surface
phenotypes obtained in the three conditions. A reproducible feature
of our previous experiments was the ability of IFN-a to enhance the
number of viable PCs (12). In contrast to IFN-a, IFN-g failed to
increase the number of PCs, even in comparison with cells main-
tained only with added IL-6 and IL-21 (Fig. 1B).
For gene expression analysis during the transition from plasma-
blast to PC, RNAwas sampled at five time points during the initial
24 h after exposure to IFN followed by subsequent sampling at 48
and 96 h (Fig. 1C). To gain an overview of the impact of IFN, we
assessed the overall pattern of the variation in gene expression.
Notably, IFN-a stimulation produced a profound change at the early
time points, showing a maximal change of 427 genes (versus no
IFN; false discovery rate 0.05) at 6 h and reaching a plateau from
12 h onwards (Fig. 1D, Supplemental Table I). Incubation with IFN-g
produced an early change in gene expression that was sustained and
gradually increased over the 5-d period. Both IFN-a and IFN-g
showed nearly equivalent induction of shared targets genes such as
STAT1 (6.3 versus 4.6 median fold induction, respectively).
These patterns of overall differential gene expression indicate that
IFN stimulation has the potential to drive changes in the regulatory
networks operating in plasmablasts, which might alter the repro-
gramming pathways that define PC identity. To further profile the
global transcriptional changes, we performed hierarchical clustering
The Journal of Immunology 3
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analysis on the 2000 most variant probes (Fig. 2). The resulting
patterns demonstrated that the majority of these gene probes dis-
played similar kinetics, regardless of culture conditions. There were
large cohorts of genes, including prototypical B cell and PC iden-
tifiers, components of secretory pathways, and genes associated
with metabolic function for which the overall pattern of regulation
was preserved in the presence or absence of IFN. Among these
genes, there were subtle differences in the kinetics for individual
donors, but the overall picture remained consistent. However, as
anticipated from the initial analysis, there were blocks of genes that
showed specific changes in response to either IFN-a or IFN-g.
Application of WGCNA to define coregulated gene modules at
the plasmablast to PC transition
The basic underlying gene regulatory networks and master regu-
lators associated with the reprogramming that accompanies dif-
ferentiation to the PC state have been extensively documented (42).
However, recent studies employing systems-scale network analy-
sis in other immune cell lineages have identified novel hub genes
responsible for coordinating molecular circuits that operate in
context-specific settings (43). To provide additional insight into
the genes and pathways that feature in differentiating ASCs at the
plasmablast to PC transition, we performed gene coexpression
network analysis on our temporal transcriptome data.
Using the WGCNATOM, we evaluated the relationship among
all gene pairs to establish sets of interdependent genes. These sets
or modules will contain common and signaling-specific molecular
circuits, allowing a greater resolution of the networks controlling
PC biology. Modules were determined based on hierarchical
clustering of genes with coordinated expression and assigned in-
dividual colors to denote membership (Fig. 3A, Supplemental
Table II). The expression of closely connected genes belonging
to network modules was then plotted as heat maps to follow the
temporal patterns of expression change (Fig. 3B). The largest
FIGURE 1. Characterization of the impact of IFN on in vitro PC generation. (A) IFN exerts minimal influence on the phenotypic maturation of human PCs as
assessed by the level of CD38 and CD138 acquisition over a period of 3 wk. Representative FACS plots gated on viable cells from a single donor are shown. (B)
Enumeration of absolute numbers of viable cells obtained at the indicated time in culture with standard media alone or with added IFN-a or IFN-g. Data from
three donors are displayed. (C) Schematic of time-course evaluation of gene expression during the transition from plasmablast to PC. Data are derived from
samples generated from three donors at eight time points. (D) The number of differentially expressed genes (false discovery rate 0.05) for the contrasts IFN-a
versus no IFN (dotted line/diamonds), IFN-a versus IFN-g (solid line/triangles), and IFN-g versus no IFN (dashed line/open triangles) at each time point.
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modules indicated by “dark orange” and “azure” showed similar
kinetics across the three conditions and varied primarily in the
magnitude of change. As module membership is determined by
expression similarity in an unsigned fashion (absolute correla-
tions), these modules contain genes that are both coordinately
upregulated and downregulated during differentiation. In contrast,
genes that are acquired in a relatively abrupt manner at a late time
point populate the third largest module “cornflower blue.” The
remaining smaller modules are more variable and may in part
reflect donor differences.
To determine the extent of overlap between modules in the
three differentiation conditions, we performed Fisher exact tests
(Fig. 3C). The results are illustrated as a heat map showing the
significance of overlap between module memberships in the
pairwise comparison of each of the three culture conditions. A
high degree of similarity between conditions was detected for
modules such as “azure,” “cornflower blue,” “dark orange,” and
“gray.” Smaller modules also exhibited significant similarity.
Notably, IFN-associated modules “brown” and “sea green” were
readily identified by the lack of overlap with modules derived
from cells cultured without IFNs. These modules showed partial
overlap in the comparison between IFN-a and IFN-g.
Signature enrichment analysis to establish module-associated
biology
To assess the underlying biological processes operating within each
module, we performed signature enrichment analysis. In this in-
stance, we separately evaluated induced and repressed genes within
modules and restricted depiction of modules to those that contained
at least five genes within a given gene ontology (GO) category
(Fig. 4). Consistent with a defining feature of PC maturation, GO
terms related to cell cycle were prominently associated with the
downregulated component of “azure” and “dark orange” modules.
Conversely, the upregulated genes in these modules were associ-
ated with a defined PC signature and included numerous compo-
nents of the unfolded protein response, such as XBP1, HERPUD1,
and DNAJB9. In addition to these shared modules linked to cell
cycle exit and secretory adaptation, B cell genes repressed by
BLIMP1 were associated with shared module “green.” This con-
firmed that the core PC processes of entry into cell cycle quies-
cence and adaption for high-level secretory state were conserved
in the presence or absence of IFN stimulation. Genes associated
with autophagy were also commonly upregulated across all three
conditions and linked to the “azure” and “dark orange” modules,
which agrees with the reported requirement for this process in
long-term PC survival (44). Another shared feature across all
conditions was the association of “cornflower blue” (up) with
EZH2 targets, consistent with data describing a role for this epi-
genetic modifier in maintaining a germinal center phenotype and
repressing transition to the PC state (45–47). Importantly, this
analysis also showed that the IFN-related “brown” and “sea
green” modules, particularly in the context of IFN-a, showed
highly significant overlap with modules identified by Chiche et al.
(30) as predictive signatures of disease activity in peripheral blood
samples from patients with SLE.
Construction of regulatory networks defining core and
inflammatory circuits
We next used the 50,000 most significant topological overlap values
(edges) to construct a gene network, identifying hub genes within
modules associated with the genetic programs of PCs generated
under the three different conditions (Fig. 5A). Although the overall
structure of large module networks was generally intact in the
three conditions, there were distinctive features, most readily
observed in the visualization of the “gray” module. This was ac-
companied by a change in the relative connectivity of hub genes,
with prominent nodes of RPS2P28, RPS2P48, and FABP5P2,
respectively. Interestingly, these genes, and many of the other
highly connected hubs within this module, are pseudogenes, which
have received increasing attention for potential roles in gene regu-
lation and disease (48). Also conspicuous were several small, isolated
networks, including the “sea green” module associated with IFN-a
exposure (surrounded by green box).
We next investigated the IFN-specific “sea green” network in
more detail (Fig. 5B). Many of the hub genes represent archetypal
IFN-responsive genes that tended to reach peak expression 6 h
poststimulation. There was also a small subset of genes, including
EIF1, SLC1A5, GLS, and FOS, that were transiently repressed in the
presence of IFN-a. The fact that two of these are related to gluta-
minolysis suggests that IFN may be able to impinge on the meta-
bolic control of PC differentiation. Moreover, the analysis points to
the transcriptional cofactor HELZ2 as a central hub in the IFN-a
response, providing an unexpected link to a regulator of adipocyte
differentiation and hepatic lipogenic gene expression (49, 50).
Large changes in the magnitude of transcript level are likely to
signify importance during a response, but may not be the only
indication of being a crucial contributor. A member of a particular
network or module may change its correlation partners over time,
allowing a diversity of outcomes by combinatorial usage. To
explore the relationships between genes within modules during
the PC differentiation process in the context of IFN-a, we ana-
lyzed the gene connectivity patterns versus expression level at
each of the sampled time points (Fig. 6). In these plots, genes
positioned centrally show neither change in expression nor
change in degree of module connectivity; however, these can still
be highly connected genes that may function during this phase of
PC maturation irrespective of additional environmental stimuli.
An example is the transcription factor KLHL6, which has pre-
viously been implicated in B cell receptor signaling and is
recurrently mutated in chronic lymphocytic leukemia (51, 52).
FIGURE 2. Longitudinal gene expression profiling of differentiating
ASCs exposed to IFN. Hierarchically clustered heat map representation of
global gene expression profiles derived from timed intervals following
exposure of human plasmablasts to no IFN, IFN-a, or IFN-g. Changes in
gene expression attributable to IFN stimulation are indicated. Row-wise,
Pearson correlation, complete linkage.
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Genes that do not appreciably change expression between con-
ditions, but change degree of connectivity may exhibit different
roles as the plasmablasts continue to differentiate under the in-
fluence of inflammatory cytokines. IL10RA falls into this cate-
gory; IL-10 is known to potentiate PC differentiation (53–55),
but our data suggest that its effect may be altered in the presence
of IFN-a. Additionally there is a cohort of genes that change in
expression, but retain a similar degree of module connectivity.
Importantly, although the degree of module connectivity may not
change, the individual genes contributing to connectivity often
change significantly. Thus, a gene may show no overall change
in degree of connectivity but entirely change the genes with
which it is connected (Supplemental Table II). As anticipated,
both STAT2 and IFN regulatory factor (IRF) 7 are examples of
this category and are highly induced during exposure to IFN-a.
Although maintaining a similar degree of module connectivity
STAT2 and IRF7 fundamentally alters the nature of genes to
which they connect, sharing only 2 and 4% of the top 100 most
connected genes between ASCs differentiating in the presence or
absence of IFN-a. These transcription factors are central to IFN-
mediated signaling and, as expected, switch their connectivity to
IFN-regulated genes upon exposure to IFN-a.
In addition to genes such as STAT2 and IRF7 that switch con-
nected genes without altering their degree of connectivity, a sub-
stantial number of genes show changes in both expression and
connectivity patterns in a sustained fashion over time. We have
highlighted examples from the peak time point (t = 6 h) of differ-
ential gene expression in ASCs treated with IFN-a. Included in this
group is the hub gene HELZ2, giving further support to context-
specific function for this transcriptional regulator. Interestingly, the
FIGURE 3. Construction of gene coexpression networks and module membership. (A) Identification of coexpressed transcripts by pairwise correlation. Highly
connected genes are displayed in a hierarchically clustered TOM. (B) Gene expression patterns within each WGCNA module. Module colors were assigned so that
maximally overlapping modules had the same color; see (C). (C) Heat map showing the number of overlapping genes between modules within two treatment
types, with the overlaps shown as numbers and the significances as the color scale (2log10 p values; Fisher exact test). Comparisons between media-
treated versus IFN-a–treated samples, media-treated versus IFN-g–treated samples, and IFN-a–treated versus IFN-g–treated samples.
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gene exhibiting the greatest difference in both expression level and
connectivity in IFN-a–treated plasmablasts was ISG15. This was
accompanied, in this group of IFN-a–induced genes, by the several
enzymatic components required for coupling of ISG15 to intracel-
lular targets. The large shift in connectivity in this group implies
that ISG15-related function may play a particular role in plasma-
blasts responding to an inflammatory environment.
The ISG15-conjugating system is a dominant functional
attribute of IFN-driven ASCs
ISG15 is highly induced in a number of cell types in response to type
I IFNs, where it can act as an ubiquitin-like molecule that covalently
attaches to Lys residues in a diverse range of target proteins in a
process termed ISGylation (16). In mice, ISG15 has been shown to
have a protective role in response to a variety of virus infections,
although the precise mechanism remains unknown (56). To deter-
mine whether ASCs exposed to IFN-a showed evidence of a
functional ISG15-conjugation pathway, we performed Western
blotting on lysates generated from in vitro–differentiated cells. Prior
to IFN-a treatment, there was no detectable ISG15 (Fig. 7A).
However, consistent with the gene expression data by 24 h after
IFN-a treatment, a prominent band corresponding to free intracel-
lular ISG15 was observed. Additionally, we detected several high
m.w. species, consistent with ISGylated protein conjugates. This
pattern was preserved throughout the time course that paralleled our
gene expression studies. We also evaluated the pattern in more
differentiated PCs obtained after 40 d of culture in the presence of
IFN-a. These cells display a phenotype resembling bone marrow
PC with high levels of CD138 (data not shown). Notably, there are a
wide range of ISGylated proteins, with pronounced species in the
molecular mass range of 25–50 kDa, indicating that the process of
ISGylation is maintained in PCs with sustained exposure to IFN-a.
A number of viral proteins have been shown to be ISGylated, and
two proteomic studies have characterized substrates from IFN-
treated cells (57, 58). To determine the nature of ISGylated pro-
teins in the primary human plasmablasts generated in our system,
we performed mass spectrometric analysis on anti-ISG15 immu-
noprecipitates. Consistent with previous publications, we detected
numerous ribosomal proteins and components of the ISG15 path-
way, including UBA7, the ISG15-activating enzyme, and UBE2L6,
the ISG15-conjugating enzyme (Fig. 7B, Supplemental Table III).
Among the targets, we also identified peptides from proteins of
particular relevance to the B cell lineage, including SYK, IRF4, and
DOCK2. To confirm that ISGylation may be involved in lineage-
specific regulation, we evaluated SYK for evidence of modification
in IFN-a–stimulated plasmablasts. Immunoprecipitation with anti-
ISG15 followed by blotting with anti-SYK revealed a band with a
molecular mass of ∼95 kDa, consistent with the conjugation of
ISG15 to endogenous SYK (Fig. 7C). Thus, plasmablasts generated
in the presence of IFN-a express both free ISG15 and a range of
proteins covalently modified by the addition of ISG15 with the
potential for lineage-specific effects.
ISG15 secretion characterizes inflammatory plasmablasts
In addition to its role in the modification of intracellular substrates,
ISG15 has been detected as a soluble product, despite the lack of
apparent signal peptide to direct secretion (59, 60). The primary
effect of extracellular free ISG15 defined to date is the stimulation
of IFN-g production (17, 18). In a recent paper, Bogunovic et al.
(19) identified ISG15 deficiency as the underlying genetic defect
associated with enhanced susceptibility to mycobacterial disease.
In this report, the lack of secretion of ISG15, principally attributed
to granulocytes, was shown to lead to a failure of NK cell–derived
IFN-g production and loss of control of mycobacterial infection.
The sustained and prominent induction of ISG15 among PCs
cultured in the presence of IFN-a is therefore of particular rele-
vance and if secreted in vivo would potentially place such PCs
alongside granulocytes as a bridge between type 1 and type 2 IFN
responses. We therefore assessed whether plasmablasts were ca-
pable of secreting ISG15.
To directly monitor secretion of ISG15, we developed an
ELISPOT assay to interrogate secretion from in vitro–generated
plasmablasts, which were cultured in the presence or absence of
IFN-a for 20 h on anti-ISG15 capture wells. Cells grown in the
absence of IFN-a produced copious amounts of IgG, but did not
secrete appreciable amounts of ISG15. In contrast, plasmablasts
grown in media containing IFN-a demonstrated active secretion of
ISG15, readily detectable by ELISPOT (Fig. 7D, top panel). We
then measured the production of soluble ISG15 from plasmablasts
isolated from the peripheral blood of healthy volunteers. In one
instance, we were able to detect ISG15 secretion from unmanip-
ulated plasmablasts; however, ex vivo stimulation with IFN-a
FIGURE 4. Functional annotation of modules detected in differentiating ASCs. Modules were resolved into groups showing up/downregulation of genes
(retaining those with SD .0.2 across time course). These were assessed for enrichment of gene signatures (p , 0.05). Heat map shows hierarchical
clustering (Pearson/complete) of a representative selection of enriched signatures, displaying enrichment/depletions as significant z-scores (p . 0.05 set to
z-score of 0). Displayed modules were restricted to ones with membership of at least five genes, and only modules with at least one signature enriched were
retained. Modules are listed by name with directionality of gene expression change indicated by the arrowhead of the appropriate color. Enriched
GO/signature terms are specified on the right of the heat map, and z-scores of enrichment or depletions are indicated with a blue-red color scale.
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resulted in increased secretion (Fig. 7D, bottom panel). The var-
iability of ISG15 secretion from freshly isolated plasmablasts
suggests that prior in vivo exposure to IFN-a can be associated
with polarization for ISG15 secretion.
The association between IFN-a and plasmablast production of
ISG15 has the potential to implicate plasmablasts/PCs in a range
of inflammatory processes. In terms of specific disease processes,
SLE provides a prime example in which an association between
autoantibody-secreting PCs and IFN-a–driven immune pathology
are linked. SLE is characterized by a diverse range of autoanti-
bodies, with recognition of at least 180 different Ags described in
patients with SLE (61). Recent clinical success with biologic
therapies such as rituximab (anti-CD20), belimumab (anti-BAFF),
and epratuzamab (anti-CD22) also strongly implicate a B cell
component in the disease (62). However, classic serological
markers of disease (such as anti-dsDNA Abs and complement)
and clinical status are frequently discordant (63). Regulation of
B cell–targeted biologics only partially normalizes these bio-
markers, which appears neither necessary nor sufficient for clini-
cal response (64, 65). Hence, in addition to the pathogenic role of
autoantibodies themselves, the potential involvement of the B cell
lineage in disease biology in a fashion independent of Ag speci-
ficity would be of great interest.
A striking feature of the modular network analysis was the strong
overlap of IFN-associated PC modules with signatures derived
from the peripheral blood of patients with SLE as indicators of
disease activity (30). Although IFN-a plays a central role, other
studies in patients with SLE also point to an association with IFN-g
signaling. Given the potential interplay between IFN-a–mediated
induction of soluble ISG15 and subsequent IFN-g production by
responding NK or T cells, we therefore directly evaluated whether
plasmablasts present in the peripheral blood of patients with SLE
showed evidence of ISG15 secretion. Plasmablasts from patients
with active disease were identified and sorted based on surface
phenotype of CD19+CD38hiCD27hi and assayed by ELISPOT
(Fig. 7E). ISG15 secretion was detected in 8 out of 10 samples and
was particularly notable in a patient with very active disease
(Supplemental Table IV). These data confirm that SLE is char-
acterized by the generation of a proinflammatory ASC population
that secretes ISG15 and identify a novel mechanism by which
inflammatory ISG15-secreting ASCs may contribute to patho-
genesis in a fashion that is independent of Ig.
Discussion
Protective immunity in part hinges on the successful and appro-
priate production of Abs. Particular biological contexts can elicit
highly variable Ab responses in terms of magnitude, kinetics,
affinity, and isotype produced. In each scenario, the outcome is
dependent upon the ordered process of transforming an activated
B cell into an Ab-secreting PC. During this transition, transcrip-
tional programs governing the B cell phenotype give way to the
program that defines secretory potential. The extent to which PCs
may acquire the capacity to secrete cytokines and other immune
modulatory products during this differentiation process is only just
beginning to be elucidated. Furthermore, the extent to which such
non-Ig secretory capacity may be imposed upon differentiated ASCs
rather than determined by the nature of the immune stimulus initiating
differentiation has not been defined. Given the dedicated secretory
capacity of the mature PC and the potential of such cells for extended
survival, such function would provide a significant contribution to
modulation of inflammatory and immune responses. The analysis
presented in this study points to the capacity of human PCs to be
polarized for proinflammatory immune modulatory function in re-
sponse to their cytokine environment in disease. This polarization for
proinflammatory function is superimposed as part of a distinct gene
expression module onto the programs governing the primary facets of
the PC state. This establishes a paradigm for functional polarization of
differentiated PCs in response to their microenvironments and points
to the potential existence of a range of functionally distinct ASCs.
Many of the central players essential for the differentiation of
B cells to PCs have been determined. However, less is known about
the impact of individual biological contexts on the underlying
regulatory programs. A recent study from Corcoran and colleagues
has provided tantalizing insights into the nature of wider tran-
scriptional differences obtained in different ASC populations (66).
For example, the authors identified that the tissue residence of the
evaluated PC biased the underlying gene expression patterns.
Additionally, they found that ASCs generated in vitro by exposure
of murine B cells to either the T-I stimulus LPS or the T-D mimic
CD40L/IL-4/IL-5 displayed a less mature transcriptional profile
when compared with in vivo counterparts, but were also charac-
terized by ∼200 unique stimulus-dependent transcripts. Our data
now provide direct evidence that ASC populations may be mod-
ified by inflammatory signals to induce functional gene modules
superimposed on the core ASC state. Rather than examine a pu-
rified population of phenotypically mature PCs that have reached
some degree of transcriptional stasis, we elected to perform a
FIGURE 5. Network analysis of differentiating ASCs reveals imposed
IFN program. (A) Networks constructed from WGCNA analysis of the
2000 most variant probes. The 50,000 most significant edges (TOM) were
visualized using Gephi. Node color, WGCNA module color; node size,
betweeness-centrality; and edge color, TOM value. Green box surrounds
the sea green 1/brown 2 IFN-a modules. (B) IFN-a drives a distinct
module of gene expression in differentiating ASCs (heat map from
Fig. 3C). The IFN-a–specific network: node/edge color, Gephi modularity
class; node size, betweeness-centrality. The heat map shows the expression
of the IFN-a–specific module probes.
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detailed temporal analysis of all responding cells to capture the
dynamics of the response. The data sets were subjected to
weighted gene correlation network analysis to define groups of
coordinately regulated genes and highlight pathways operating
during differentiation. This analysis has the potential to uncover
previously unanticipated players in the regulation of PC differ-
entiation, thus providing a resource for further exploration of
potential core transcriptional regulators of PC differentiation.
Moreover, rather than comparing the effect of initial stimuli that
impose a change on B cells, we instead focused on the window of
FIGURE 6. Connectivity measure of differentially expressed genes identifies the ISG15-related pathway as a key feature of ASCs generated in the
presence of IFN-a. (A) Diagrammatic representation of plots generated to assess intramodule gene connectivity versus gene expression. (B) Observed
changes in connectivity and expression patterns following IFN-a treatment at the indicated time points. x-axis, normalized (0–1) intramodular connectivity;
y-axis, Limma T-statistic for IFN-a versus no IFN. Vertical dotted lines at 60.285 connectivity; horizontal dotted lines at 63 T-statistic. Blue dots,
significant expression change; red dots, significant expression/connectivity change; green dots, highly connected. (C) Detailed view of connectivity/
expression changes induced by IFN-a treatment at 6 h. The genes with the greatest change in gene expression value are shown in the table on the right,
a selection of which are annotated on the plot on the left.
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plasmablast to PC transition. We reasoned that plasmablasts are
likely to encounter novel signals as they transit from the site of
initial stimulation that may have short- or long-term effects on gene
expression. In particular, we were interested in the effect of IFN,
given its association with PC survival and autoimmune pathology.
The emergence of the ISG15-conjugating system as the most
prominent pathway associated with IFN-a–treated plasmablasts
suggested that ISG15 or modification of cellular proteins by
ISG15 could potentially alter functional output. Upon examination
of IFN-a–stimulated plasmablasts, we detected a rapid and pro-
longed induction of both unconjugated ISG15 and numerous
ISGylated substrates. In PCs that were maintained in the presence
of IFN-a for an extended period (36 d), prominent ISGylated
proteins were detected, indicating that sustained contact with IFN-a
leads to a gradual increase in the accumulation of ISGylated
proteins. Previous studies investigating the effect of modification of
proteins by ISG15 have identified a range of effects. For example,
ISGylation of 4EHP enhances m7GTP cap structure-binding activity
to suppress translation (67), whereas modification of IRF3 inhibits
ubiquitin-mediated degradation resulting in sustained activation
(68). In most instances, the focus has been on the impact of ISG15
on the antiviral properties imparted by IFN-a. To explore the
consequences of expressing ISG15 in a setting detached from in-
fection, we performed mass spectrometry on ISG15 immunopre-
cipates prepared from IFN-a treated plasmablasts. Although the
majority of targets were consistent with previous reports, we
identified several novel ISGylated proteins of particular relevance to
the B-cell lineage and confirmed that a fraction of the tyrosine
kinase SYK contains this previously uncharacterized posttransla-
tional modification. The impact on SYK function remains to be
determined; however, ISG15 is conjugated to lysine residues of
target substrate proteins in a similar fashion to ubiquitin. As SYK
has previously been shown to be ubiquitinated after GPVI activa-
tion in platelets resulting in enhanced activity (69), it is tempting to
speculate that ISG15 modification has an analogous effect. Indeed,
a unique population of memory-like B cells expressing high levels
of SYK has been identified in patients with SLE (70), in whom
exposure to IFN-a drives expression of ISG15.
Most of the work to date on ISG15 has focused on the intracellular
modification of proteins; however, recent data have revitalized an
interest in the function of the secreted molecule. The identification of
patients lacking ISG15 has confirmed in vitro observations that
production of IFN-g is a major physiological consequence of en-
counter with secreted ISG15 (19). In the setting of mycobacterial
infection, lack of ISG15 secretion in affected patients was largely
attributed to production by neutrophils, although lymphocyte pop-
ulations also have the capacity to secrete ISG15. Our data now
document the capacity of plasmablasts and PCs, cell types spe-
cialized for high-level secretion, to produce soluble ISG15. Most
importantly, we provide evidence of ISG15 secretion from ASCs in
patients with active SLE, thus linking this aspect of ISG15 function
to inflammatory disease.
Murine models of lupus and genetic association studies have
long indicated a role for type 1 IFN in the pathogenesis of SLE
(10), and endeavors characterizing type 1 IFN–induced tran-
scripts in blood and tissue samples from patients with SLE have
confirmed a significant connection to IFN-a in particular (38–
41). Although IFN-a has been considered to lie at the heart of
lupus-associated pathology, there have been a number of reports
that provide evidence for a contribution to the disease-associated
signature by type 2 IFN (71–73). Most recently, Chichel et al.
(30) have employed modular transcriptional repertoire analysis
to monitor the dynamics of IFN signatures across patients with
SLE and within individuals over time. They identified three
distinct modules that were differentially associated with disease
severity, with notable representation of IFN-b– and IFN-g–
driven transcripts in the modules typifying patients with active
disease. Thus, the progression of the disease may mirror a
transition from type 1 to type 2 IFN involvement. Given that, the
SLE IFN signature also contains a PC-related module absent in
other diseases with prominent IFN-inducible gene profiles such
as tuberculosis (29). Indeed, it has been shown that CD19-
enriched cells are a source of IFN module gene expression in
SLE, including ISG15 and correlating with the SLE Disease
Activity Index score (74). Moreover, in active SLE, CD19-
enriched cells also display gene expression patterns consistent
with ASC differentiation. Taken in conjunction with our data,
this would be consistent with the principle origin of IFN sig-
natures from CD19+ ASCs. Because ISG15 can act as a bridge
between type 1 and type 2 IFN through the activation of NK cells
and T cells, these data fit with a model in which the secretion of
soluble ISG15 by ASCs contributes to the shift toward IFN-g in
more aggressive disease.
The secretion of functional products other than Ig by PCs has
now been documented in range of disease contexts, including the
FIGURE 7. ASCs show evidence of protein ISGylation and ISG15 se-
cretion. (A) ASCs generated in the presence of IFN-a show induction of
unconjugated ISG15 and higher m.w. ISGylated proteins analyzed by
Western blotting with anti-ISG15. (B) Mass spectrometry performed on
samples immunoprecipitated with anti-ISG15 identifies substrates of
ISGylation in plasmablasts stimulated with IFN-a for 24 h. Identified
proteins are shown as a wordle with the number of peptide hits represented
by font size. (C) Validation of ISGylation of SYK. Lysates generated from
IFN-a–stimulated plasmablasts were immunoprecipitated (IP) with control
rabbit IgG or anti-ISG15 and evaluated by Western blotting with anti-SYK.
(D) Top panel, Secreted ISG15 detected by ELISPOT in plasmablast cul-
tures derived from purified B cells in vitro, 20 h after exposure to IFN-a.
Detection of secreted IgG in replicate cultures is shown for comparison. (D)
Bottom panel, Plasmablasts purified from the peripheral blood of healthy
volunteers were assayed for ISG15 production by ELISPOT 24 h after in-
cubation in media alone or containing IFN-a. (E) Representative ELISPOT
detecting spontaneous production of ISG15 by plasmablasts obtained from
the peripheral blood of a patient with SLE.
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development of an SLE-like disease in Lyn-deficient mice. In this
instance, the secretion of IL-10 by ASCs provided protection
against inflammation caused by myeloid and T cell activation (75).
Immunosuppressive PCs have also been demonstrated in a murine
model of Salmonella Typhimurium infection in which IL-10–
expressing CD19+CD138+ cells were detected within 24 h of ad-
ministering the bacteria (8). This finding was solidified in a further
study that matched the level of IL-10 secretion to the maturation
stage of ASC populations in animals challenged with Salmonella
(5). The phenotypically most mature cells that expressed high levels
of Prdm1 and Irf4 also expressed the highest levels of IL-10. These
results were bolstered by a similar observation in the setting of
experimental autoimmune encephalomyelitis in which CD138hi
PCs were the major B cell–derived source of IL-10. Moreover, PCs
in both models of disease also produced the immunosuppressive
cytokine IL-35; however, the two cytokines were not detected si-
multaneously, suggesting that PCs or their precursors might dif-
ferentially respond to initial triggers.
The abovemodels suggest a strong association between PCs and the
suppression of inflammation. However, cytokine production by PCs is
not limited to those with anti-inflammatory properties. In two
further murine models that generate polyclonal PC responses, there is
strong evidence that the major source of critical proinflammatory
cytokines is a PC population. In the first instance, the authors described
the contribution of PC-produced IL-17 to the control of acute
Trypanonsoma cruzi infection (4). In this report, a trans-sialidase
produced by the parasite was identified that could directly stimulate
primary mouse or human B cells to make IL-17 using a retinoic
acid–related orphan receptor gt–independent transcriptional program.
In the second example, IgM-secreting CD138+ PCs were shown to
account for ∼75% of GM-CSF–expressing cells in the spleen in a
murine model of sepsis (76). Deletion of these cells had a profound
impact on bacterial clearance and culminated in septic shock.
Not only do PCs contribute in novel ways during infection, they
also participate in maintaining the homeostatic balance of the
gastrointestinal tract. The production of IgA by mucosal-associated
PCs is an essential component of gut homeostasis and is initiated by
exposure of B cells to inducible NO synthase and TNF-a. Sur-
prisingly, IgA+ PCs resident in the lamina propria of the small
intestine were shown to be the primary local source for both these
pathways (3). An engineered inability of B-lineage cells to secrete
inducible NO synthase and TNF-a had a compound effect on gut
biology, including loss of IgA production, altered microbiota
composition, and diminished response to the pathogen Citrobacter
rodentium. Thus, PCs in the microenvironment of the gut are
identified as crucial effectors, both in terms of the Ig as well as the
cytokines they secrete.
The current body of data indicate a diverse role for ASCs beyond
the primary task of Ig production. Although most of the examples
described thus far arise in the context of stimulation through
microbial-derived molecules, it seems likely that alternative signals
will generate PCs with distinct secretory profiles. In particular, our
data are consistent with an inflammatory niche-driven generation of
ISG15-secreting PCs. Additionally, the documentation of activating/
prosurvival signals provided by diverse cells contributing to the
multicomponent PC niche (77), such as eosinophils, megakaryo-
cytes, and basophils, suggests that other settings may be able to
impart unique functional capabilities to the responding PCs (78,
79). Given the new range of activities that can be attributed to
ASCs, one of the challenges will be to determine the extent to
which these cells remain committed to a particular phenotype. One
can envision at least three scenarios that give rise to functionally
distinct PC subsets: 1) a deterministic model in which B cells with a
pre-established program differentiate into a fixed polarized effector; 2)
an instructive model in which B cells initiate differentiation in
a polarizing context leading to a fixed polarized effector; or 3) a
responsive model in which established ASCs are exposed to a
polarizing context that generates labile polarized effectors. Our
results suggest that cells committed to Ab secretion are indeed
malleable in different environmental conditions and point to as yet
undiscovered roles for PC contribution to immune regulation.
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